The increasing frequency of avian influenza outbreaks worldwide is accelerating the growth of the global avian influenza vaccine market, according to a report by Exactitude Consultancy.
Expanding poultry meat and egg production, government-led vaccination campaigns, and advances in recombinant and vector vaccine technology are reinforcing this trend. Greater emphasis on animal health surveillance and traceability is also supporting market growth.
Exactitude Consultancy projects the market, valued at USD 1.34 billion in 2024, will reach USD 2.19 billion by 2034. This represents a compound annual growth rate of 5.0 percent during 2025–2034. Rising concerns over zoonotic transmission, trade losses, and food security have positioned vaccination as a critical component of animal health management across Asia, Europe, and the Americas.
Market condition and evolving trends
Avian influenza, commonly known as bird flu, continues to threaten poultry populations worldwide, affecting both commercial farms and backyard systems.
To mitigate economic and public health risks, governments and producers are adopting preventive vaccination strategies alongside enhanced biosecurity measures.
Traditional inactivated virus vaccines remain the backbone of disease control programs, accounting for more than 60% of market share. However, next-generation recombinant and vector-based vaccines are gaining traction. These advanced formulations provide broad, cross-protective immunity and enable differentiation of infected from vaccinated animals (DIVA) strategies.
The growing frequency of highly pathogenic avian influenza (HPAI) outbreaks and the rise in industrial-scale poultry farming are further accelerating vaccine demand.
“Avian influenza vaccination is no longer optional; it’s an essential pillar of global food security. With advances in recombinant and vector-based vaccines, producers can now achieve broader immunity and sustainable disease control,” said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
Emerging opportunities and challenges
Between 2025 and 2034, Exactitude Consultancy expects the market to evolve toward universal and recombinant formulations capable of addressing multiple viral strains.
Between 2025 and 2034, Exactitude Consultancy expects the market to evolve toward universal and recombinant formulations capable of addressing multiple viral strains.
Regionally, Asia Pacific is projected to remain the largest market due to high poultry density and frequent virus recurrence. Europe and North America are expected to adopt innovative DIVA-compatible vaccines that balance disease control with trade policies.
Their report concluded that:
- The global avian influenza vaccine market stands at the crossroads of biotechnology and food security.
- As outbreaks become more frequent and economic stakes rise, innovation in next-generation vaccines and real-time monitoring systems will be critical for sustainable poultry health management.
- Manufacturers investing in recombinant platforms, scalable production, and international collaborations are best positioned for the next phase of global growth.